公开(公告)号：WO2010028338A2

公开(公告)日：2010-03-11

申请号：PCT/US2009/056179

申请日：2009-09-08

Applicant: ABBOTT LABORATORIES ,  CARROLL, William, A. ,  DART, Michael, J. ,  FROST, Jennifer, M. ,  KOLASA, Teodozyj ,  LI, Tongmei ,  LIU, Bo ,  PEREZ-MEDRANO, Arturo ,  PATEL, Meena ,  WANG, Xueqing ,  PEDDI, Sridhar

Inventor： CARROLL, William, A. ,  DART, Michael, J. ,  FROST, Jennifer, M. ,  KOLASA, Teodozyj ,  LI, Tongmei ,  LIU, Bo ,  PEREZ-MEDRANO, Arturo ,  PATEL, Meena ,  WANG, Xueqing ,  PEDDI, Sridhar

IPC: C07D277/46 ,  C07D417/06 ,  C07D417/14 ,  A61K31/427 ,  A61P29/00

CPC classification number: C07D417/06 ,  C07D277/46 ,  C07D417/14

Abstract: The present application relates to cannabinoid receptor ligands of formula (I), wherein X 1 , A 1 , R x , R 2 , R 3 , R 4 , and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

Abstract translation: 本申请涉及式（I）的大麻素受体配体，其中X1，A1，Rx，R2，R3，R4和z如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。

公开(公告)号：WO2008121558A1

公开(公告)日：2008-10-09

申请号：PCT/US2008/057460

申请日：2008-03-19

Applicant: ABBOTT LABORATORIES ,  CARROLL, William A ,  KOLASA, Teodozyi ,  FROST, Jennifer M ,  DART, Michael J ,  PATEL, Meena V ,  LATSHAW, Steven P ,  PEREZ-MEDRANO, Arturo ,  WANG, Xueqing ,  PEDDI, Sridhar

Inventor： CARROLL, William A ,  KOLASA, Teodozyi ,  FROST, Jennifer M ,  DART, Michael J ,  PATEL, Meena V ,  LATSHAW, Steven P ,  PEREZ-MEDRANO, Arturo ,  WANG, Xueqing ,  PEDDI, Sridhar

IPC: C07D277/46 ,  A61K31/426 ,  A61K31/427 ,  A61K31/429 ,  C07D417/06 ,  C07D417/12 ,  C07D513/04

CPC classification number: C07D277/46 ,  C07D417/06 ,  C07D417/12 ,  C07D513/04 ,  Y02P20/582

Abstract: The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, R4, L2 and A are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本申请涉及含有噻唑类的式（I）化合物，其中R 1，R 2，R 3，R 4，L 2和A如说明书中所定义。 还公开了包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。

公开(公告)号：WO2006017406A1

公开(公告)日：2006-02-16

申请号：PCT/US2005/027115

申请日：2005-07-29

Applicant: ABBOTT LABORATORIES ,  PEDDI, Sridhar ,  CARROLL, William, A. ,  PEREZ-MEDRANO, Arturo ,  FLORJANCIC, Alan, S.

Inventor： PEDDI, Sridhar ,  CARROLL, William, A. ,  PEREZ-MEDRANO, Arturo ,  FLORJANCIC, Alan, S.

IPC: C07C261/04 ,  C07D333/24 ,  C07D295/135 ,  C07D401/12 ,  A61K31/381 ,  A61K31/4406 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/5375 ,  A61K31/155 ,  A61P19/02 ,  A61P25/28 ,  A61P29/00 ,  A61K31/166 ,  C07D213/56

CPC classification number: C07D295/135 ,  C07C261/04 ,  C07D213/58 ,  C07D215/12 ,  C07D317/60 ,  C07D319/18

Abstract: cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R 1 - R 12 are as defined in the specification act as antagonists of the P2X 7 receptor. These compounds are particularly useful in the treatment of pain, inflammation and neurodegeneration states.

Abstract translation: 式（I）和（II）的氰酰脒化合物及其衍生物，其中R <

公开(公告)号：WO2012067822A1

公开(公告)日：2012-05-24

申请号：PCT/US2011/058939

申请日：2011-11-02

Applicant: ABBOTT LABORATORIES ,  XU, Xiandong ,  VAN CAMP, Jennifer ,  SCANIO, Marc J. ,  BUNNELLE, William H. ,  SHI, Lei ,  OSUMA, Augustine T. ,  DEGOEY, David ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar ,  PATEL, Jyoti R.

Inventor： XU, Xiandong ,  VAN CAMP, Jennifer ,  SCANIO, Marc J. ,  BUNNELLE, William H. ,  SHI, Lei ,  OSUMA, Augustine T. ,  DEGOEY, David ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar ,  PATEL, Jyoti R.

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00

CPC classification number: C07D487/04

Abstract: Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Abstract translation: 本文公开了式（I）的KCNQ钾通道调节剂，其中R 1，R 2，R 3，R 4和R 5如说明书中所定义。 包含这些化合物的组合物; 还描述了使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：WO2011066168A1

公开(公告)日：2011-06-03

申请号：PCT/US2010/057224

申请日：2010-11-18

Applicant: ABBOTT LABORATORIES ,  BROWN, Brian, S. ,  LI, Tongmei ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar

Inventor： BROWN, Brian, S. ,  LI, Tongmei ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar

IPC: C07D237/24 ,  C07D401/12 ,  C07D405/04 ,  C07D471/04 ,  C07D495/04 ,  A61K31/502 ,  A61P29/00

CPC classification number: C07D237/24 ,  C07D401/12 ,  C07D405/04 ,  C07D471/04 ,  C07D495/04

Abstract: Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring Z 1 , R 1 , p, R 3 , and R 4 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Abstract translation: 本文公开了式（I）的KCNQ钾通道调节剂，其中环Z1，R1，p，R3和R4如说明书中所定义。 包含这些化合物的组合物; 还描述了使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：WO2007056046A1

公开(公告)日：2007-05-18

申请号：PCT/US2006/042777

申请日：2006-11-02

Applicant: ABBOTT LABORATORIES ,  CARROLL, William, A. ,  FLORJANCIC, Alan, S. ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar

Inventor： CARROLL, William, A. ,  FLORJANCIC, Alan, S. ,  PEREZ-MEDRANO, Arturo ,  PEDDI, Sridhar

IPC: C07D249/06 ,  C07D249/08 ,  C07D401/14 ,  C07D405/06 ,  C07D405/04 ,  C07D401/06 ,  C07D401/04 ,  C07D409/06 ,  C07D401/12 ,  C07D409/14 ,  C07D409/12 ,  A61K31/4192 ,  A61K31/4196 ,  A61P25/00

CPC classification number: C07D249/06 ,  C07D249/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/06 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14

Abstract: The invention is directed to compounds that are P2X 7 antagonist and have the formula (I) or (II) or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or a combination thereof, wherein R 1 , R 2 , and R 3 are defined in the specification. The invention is also directed to a method of selectively inhibiting P2X 7 activity comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (III), (IV) or (V) wherein R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are defined in the specification.

Abstract translation: 本发明涉及P2X 7拮抗剂并具有式（I）或（II）的化合物或其药学上可接受的盐，前药，前药或其组合的盐，其中R _{和R 11在本说明书中定义。}

公开(公告)号：WO2010111572A1

公开(公告)日：2010-09-30

申请号：PCT/US2010/028790

申请日：2010-03-26

Applicant: ABBOTT LABORATORIES ,  CARROLL, William A ,  DART, Michael J. ,  FROST, Jennifer M. ,  LATSHAW, Steven P. ,  LI, Tongmei ,  LIU, Bo ,  PEDDI, Sridhar ,  WANG, Xueqing ,  KOLASA, Teodozyi ,  NELSON, Derek W. ,  PEREZ-MEDRANO, Arturo

Inventor： CARROLL, William A ,  DART, Michael J. ,  FROST, Jennifer M. ,  LATSHAW, Steven P. ,  LI, Tongmei ,  LIU, Bo ,  PEDDI, Sridhar ,  WANG, Xueqing ,  KOLASA, Teodozyi ,  NELSON, Derek W. ,  PEREZ-MEDRANO, Arturo

IPC: C07D405/06 ,  C07D413/06 ,  C07D417/06 ,  A61K31/433 ,  A61P25/04

CPC classification number: C07D417/06 ,  C07D405/06 ,  C07D413/06

Abstract: Disclosed herein are compounds of formula (I) wherein Ring A and R 1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.

Abstract translation: 本文公开了式（I）的化合物，其中环A和R 1如说明书中所定义。 还公开了包含这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗病症和障碍的方法。

公开(公告)号：WO2010071783A1

公开(公告)日：2010-06-24

申请号：PCT/US2009/068173

申请日：2009-12-16

Applicant: ABBOTT LABORATORIES ,  FROST, Jennifer, M. ,  LATSHAW, Steven, P. ,  DART, Michael, J. ,  CARROLL, William, A. ,  PEREZ-MEDRANO, Arturo ,  KOLASA, Teodozyj ,  PATEL, Meena ,  NELSON, Derek, W. ,  LI, Tongmei ,  PEDDI, Sridhar ,  WANG, Xueqing ,  LUI, Bo

Inventor： FROST, Jennifer, M. ,  LATSHAW, Steven, P. ,  DART, Michael, J. ,  CARROLL, William, A. ,  PEREZ-MEDRANO, Arturo ,  KOLASA, Teodozyj ,  PATEL, Meena ,  NELSON, Derek, W. ,  LI, Tongmei ,  PEDDI, Sridhar ,  WANG, Xueqing ,  LUI, Bo

IPC: C07D277/46 ,  C07D417/12 ,  C07D513/04 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61P3/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P29/00 ,  A61P35/00

CPC classification number: C07D417/12 ,  C07D277/46 ,  C07D513/04

Abstract: Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L 1 , A 1 , R 1g , z, R 2 , R 3 , and R 4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Abstract translation: 本文公开了式（I）的大麻素受体配体，其中L1，A1，R1g，z，R2，R3和R4如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。

公开(公告)号：WO2008079687A1

公开(公告)日：2008-07-03

申请号：PCT/US2007/087175

申请日：2007-12-12

Applicant: ABBOTT LABORATORIES ,  PEREZ-MEDRANO, Arturo ,  LI, Tongmei ,  PEDDI, Sridhar ,  CARROLL, William A ,  DART, Michael J

Inventor： PEREZ-MEDRANO, Arturo ,  LI, Tongmei ,  PEDDI, Sridhar ,  CARROLL, William A ,  DART, Michael J

IPC: C07D277/18 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61K31/4709 ,  A61P9/00 ,  A61P11/00 ,  A61P29/00 ,  A61P35/00

CPC classification number: C07D277/18 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to thiazolidinylidene containing compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Abstract translation: 本发明涉及含有噻唑烷亚基的式（I）化合物，其中R 1，R 2，R 3，R 4， R 5，R 6和X如说明书中所定义，包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法 。

公开(公告)号：WO2007140385A3

公开(公告)日：2007-12-06

申请号：PCT/US2007/069921

申请日：2007-05-30

Applicant: ABBOTT LABORATORIES ,  DART, Michael J. ,  CARROLL, William A. ,  FLORJANCIC, Alan S. ,  FROST, Jennifer M. ,  GALLAGHER, Megan E. ,  LI, Tongmei ,  NELSON, Derek W. ,  PATEL, Meena V. ,  PEDDI, Sridhar ,  PEREZ-MEDRANO, Arturo ,  RYTHER, Keith B. ,  TIETJE, Karin Rosemarie ,  KOLASA, Teodozyj

Inventor： DART, Michael J. ,  CARROLL, William A. ,  FLORJANCIC, Alan S. ,  FROST, Jennifer M. ,  GALLAGHER, Megan E. ,  LI, Tongmei ,  NELSON, Derek W. ,  PATEL, Meena V. ,  PEDDI, Sridhar ,  PEREZ-MEDRANO, Arturo ,  RYTHER, Keith B. ,  TIETJE, Karin Rosemarie ,  KOLASA, Teodozyj

IPC: C07D277/46 ,  C07D277/48 ,  C07D277/60 ,  C07D277/82 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61P29/00

Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.